Immunome
IMNM
25 hedge funds and large institutions have $19.5M invested in Immunome in 2020 Q4 according to their latest regulatory filings, with 25 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
19.11% more ownership
Funds ownership: 0% → 19.11% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AGM
Alpine Global Management
New York
|
+$9.22M |
| 2 |
PCM
Prentice Capital Management
Greenwich,
Connecticut
|
+$4.86M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.97M |
| 4 |
Cerity Partners
New York
|
+$1.43M |
| 5 |
BlackRock
New York
|
+$837K |
Top Sellers
IMNM Hedge Fund Activity: Q4 2020 in Review
25 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q4 2020, worth a combined $19.5M.
Buyers outnumbered sellers: 25 funds opened new IMNM positions and 0 closed out — a net gain of 25 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Alpine Global Management, opening a new position worth an estimated $9.22M.
- 25 institutional investors held Immunome (IMNM) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $19.5M of Immunome stock for Q4 2020.
- 25 funds opened new Immunome positions in Q4 2020 and 0 closed out, a net change of +25 holders.
- The largest Immunome buyer in Q4 2020 was Alpine Global Management, an estimated $9.22M added.
Based on aggregated 13F filings for Q4 2020.